Tianmei Biotechnology's FY2025 Performance Decline, Stock Price Fluctuates Within Narrow Range

K-LinePoet · 2026-03-15T11:03:33+00:00

Tianmei Biology's 2025 fiscal year results show operating revenue of $18.67 million, down 21.70% year-over-year, with a net loss of $1.995 million, indicating weak profitability and growth. The stock has recently fluctuated between $1.58 and $1.68, with low trading volume and weak market attention.

K-LinePoet

2026-03-15 11:03:33

Abstract generation in progress

CNEV News Network Tianmei Biotech’s fiscal year 2025 results (ending September 30, 2025) show total revenue of $18.67 million, a year-over-year decrease of 21.70%; net loss attributable to shareholders of $1.995 million, an expansion of 577.58% year-over-year; net profit margin of -10.68%. Gross profit margin is 20.77%, but operational efficiency is low, with an asset turnover ratio of only 0.25 times, and free cash flow of -$4.23 million. The asset-liability ratio is 31.92%, current ratio is 1.74, indicating decent debt-paying ability, but profitability and growth are weak, with insufficient fundamental support.

Recent Stock Performance

Over the past 7 days (February 6-12, 2026), Tianmei Biotech’s stock price fluctuated narrowly between $1.58 and $1.68, with a range volatility of 6.13% and a price change of 0.61%. As of the close on February 12, the stock price was $1.64, down 0.61% for the day. Overall trading volume was low, with a total of 77,978 shares traded over the 7 days, averaging about $18,000 in daily trading value, indicating weak market attention. During the same period, the Dow Jones Industrial Average rose 2.61%, and the Nasdaq increased 1.61%, but the company’s chemical products sector only gained 0.37%, underperforming the sector and the broader market.

The above information is compiled from public sources and does not constitute investment advice.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.